Multiple CCR5 Conformations on the Cell Surface Are Used Differentially by Human Immunodeficiency Viruses Resistant or Sensitive to CCR5 Inhibitors

The structural basis of agonist-induced activation in constitutively active rhodopsin

(2011) Jörg Standfuss et al.   NATURE

Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41

(2011) Cleo G. Anastassopoulou et al.   VIROLOGY

HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry

(2010) John C. Tilton et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection

(2010) Javier Garcia-Perez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors

(2010) Q. Hu et al.   JOURNAL OF GENERAL VIROLOGY

Tracking G-protein-coupled receptor activation using genetically encoded infrared probes

(2010) Shixin Ye et al.   NATURE

Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5

(2010) Robert A. Ogert et al.   VIROLOGY

Characterization of a Human Immunodeficiency Virus Type 1 V3 Deletion Mutation That Confers Resistance to CCR5 Inhibitors and the Ability To Use Aplaviroc-Bound Receptor

(2009) K. M. Nolan et al.   JOURNAL OF VIROLOGY

Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41

(2009) C. G. Anastassopoulou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex

(2009) X. J. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The apparent cooperativity of some GPCRs does not necessarily imply dimerization

(2009) Marc Chabre et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry

(2009) Reem Berro et al.   PLoS Pathogens

Involvement of the Second Extracellular Loop and Transmembrane Residues of CCR5 in Inhibitor Binding and HIV-1 Fusion: Insights into the Mechanism of Allosteric Inhibition

(2008) Kenji Maeda et al.   JOURNAL OF MOLECULAR BIOLOGY

In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject

(2008) A. M. N. Tsibris et al.   JOURNAL OF VIROLOGY

High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation

(2008) C. Altenbach et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120

(2008) Robert A. Ogert et al.   VIROLOGY

Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors

(2008) Pavel Pugach et al.   VIROLOGY